FTC Expands Patent Listing Challenges Against Pharmaceuticals

The Federal Trade Commission sent warning letters to companies and notified the FDA that it disputes the accuracy of more than 300 Orange Book patent listings across 20 different brand name products, according to statement.

• Warning letters were sent to AstraZeneca and Novo Nordisk for obesity and type-2 diabetes injectable drugs
  • Boehringer Ingelheim, Covis Pharma, Glaxo-Smith Kline, Novartis Pharmaceuticals Corp., Teva Pharmaceutical Industries Ltd. and some of their subsidiaries for asthma and COPD inhalers
  • Amphastar Pharmaceuticals Inc. for a glucagon nasal spray to treat severe hypoglycemia in type-1 diabetics

To contact the reporter on this story:
Maria ...